ReviewDrug design, development and therapy2010
Interleukin-6 inhibition for treatment of rheumatoid arthritis: a review of tocilizumab therapy.
Review in Drug design, development and therapy, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.
- Serum Levels of IL-6 and TNF-α May Correlate with Activity and Severity of Rheumatoid Arthritis.Medical science monitor : international medical journal of experimental and clinical research · 2015Pooled it
- Interleukin-6 and cytochrome-P450, reason for concern?Rheumatology international · 2012Pooled it
- Tofacitinib Therapy for Rheumatoid Arthritis: A Direct Comparison Study between Biologic-naïve and Experienced Patients.Internal medicine (Tokyo, Japan) · 2018Trial
- Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy.Arthritis research & therapy · 2017Trial
- Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study.Annals of the rheumatic diseases · 2015Trial
- Acute exposure to 50-Hz magnetic fields increases interleukin-6 in young healthy men.Journal of clinical immunology · 2011Trial
- Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics.Frontiers in oncology · 2022Review
- Translating Evidence from Clonal Hematopoiesis to Cardiovascular Disease: A Systematic Review.Journal of clinical medicine · 2020Review
- Association of Interleukin 6 Receptor Variant With Cardiovascular Disease Effects of Interleukin 6 Receptor Blocking Therapy: A Phenome-Wide Association Study.JAMA cardiology · 2018Article
- Periodontal, salivary and IL-6 status in rheumatoid arthritis patients. A cross-sectional study.Medicina oral, patologia oral y cirugia bucal · 2017Article
- A novel approach to genome-wide association analysis identifies genetic associations with primary biliary cholangitis and primary sclerosing cholangitis in Polish patients.BMC medical genomics · 2017Article
- Dosing of Intravenous Tocilizumab in a Real-World Setting of Rheumatoid Arthritis: Analyses from the Corrona Registry.Rheumatology and therapy · 2016Article
- Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date.Drug design, development and therapy · 2016Review
- Reduced dose of tocilizumab for the maintenance of remission in patients with rheumatoid arthritis: a clinical experience.Rheumatology international · 2015Article
- Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.Genes & development · 2015Article
- IL-6 trans-signaling increases expression of airways disease genes in airway smooth muscle.American journal of physiology. Lung cellular and molecular physiology · 2015Article
- Review of Systemic Immunosuppression for Autoimmune Uveitis.Ophthalmology and therapy · 2014Review
- Clinical and ultrasound evaluation of the response to tocilizumab treatment in patients with rheumatoid arthritis: a case series.Rheumatology international · 2014Article
- Does tocilizumab contribute to elevation of rheumatoid factor and induction of paradoxical syaloadenitis in rheumatoid arthritis patients?Wiener klinische Wochenschrift · 2014Article
- Severe Pulmonary Suppuration with Infection-Induced Systemic Inflammatory Response Syndrome following Tongue Cancer Surgery in a Patient Undergoing Tocilizumab Therapy for Rheumatoid Arthritis.Case reports in dentistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The dawn of the biologic era has been an exciting period for clinical research and patient care in rheumatoid arthritis (RA). Targeted biologic therapies have changed the outcome of this disease and made remission a realistic outcome for many patients. Tocilizumab (TCZ, Actemra(®)), is a humanized monoclonal antibody against the interleukin 6 receptor and has been approved in many countries for the treatment of moderate to severe RA. There have been a number of important clinical trials demonstrating the efficacy of TCZ in active rheumatoid arthritis. This review summarizes the data on efficacy, patient-reported outcomes, adverse events, and safety from some of these trials. Current trends in clinical practice will be discussed. It is difficult to place TCZ and many new medications in the algorithm of treatment at present. However, the next few years will hopefully reveal their role as we better define abnormal immune processes in individuals with RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.